Category: Functional Bowel Disease
Samuel A. Eberlein
Cedars-Sinai Center for Outcomes Research and Education
Los Angeles, CA
We conducted a conjoint analysis survey among patients with Rome IV IBS and ≥2 episodes of acute abdominal pain with an average severity of ≥4 (0-11 scale) in the past month. The conjoint uses a “choice tournament” exercise to assess the relative importance of medication attributes (e.g., route of administration [oral vs. subcutaneous (SQ)], efficacy at reducing pain, risk of side effects) in their decision making, characterized as a percentage weight. Our survey also assessed their willingness to use a SQ therapy modeled after ROSE-010, which is in the human clinical trial phase.
Results: Overall, 461 individuals with Rome IV IBS and recurrent pain episodes completed the survey; Tables 1 and 2 present their demographics and IBS characteristics, respectively. Through the conjoint analysis, we found that patients prioritized medication efficacy (importance score 34.9%), chance of nausea (24.3%), and chance of constipation (12.2%) as most important in their decision making. These were followed by route of administration (10.3%), chance of headache (9.3%), and chance of drowsiness (8.9%). In regression analysis, demographics and IBS characteristics were largely unpredictive of decision-making preferences.
We found, in general, that 431 (93.5%) participants would consider using a SQ therapy for their pain. When presented a SQ medication profile (benefits and side effects) modeled after ROSE-010, 202 (43.8%) individuals reported that they would use it most of the time or always for their acute pain. The Figure shows respondents’ familiarity with SQ medicines stratified by their willingness to use ROSE-010; increasing familiarity with self-injectable therapies was associated with higher willingness to use ROSE-010.
Discussion: Those with Rome IV IBS prioritize efficacy when selecting among therapies for acute pain and the vast majority are open to SQ treatments. This calls for the development of novel, effective treatments—oral and SQ—for management of acute IBS pain.
TABLE 1. Demographics of the study population (N=461).
TABLE 2. Study cohort’s IBS characteristics (N=461).
FIGURE. Respondents’ familiarity with SQ medicines stratified by their willingness to use a ‘specific’ SQ medication modeled after ROSE-010 for treatment of their acute abdominal pain (n=410). Increasing familiarity with self-injectable therapies was associated with higher willingness to use ROSE-010 SQ, subcutaneous.
Samuel Eberlein indicated no relevant financial relationships.
Christopher Almario: Alnylam Pharmaceuticals – Consultant. Arena Pharmaceuticals – Consultant. My Total Health – Stockholder/Ownership Interest (excluding diversified mutual funds).
Carine Khalil indicated no relevant financial relationships.
Brennan Spiegel: Arena Pharmaceuticals – Advisory Committee/Board Member. Ironwood Pharmaceuticals – Advisory Committee/Board Member, Grant/Research Support. Salix Pharmaceuticals – Advisory Committee/Board Member. Takeda Pharmaceuticals; – Advisory Committee/Board Member, Grant/Research Support.